Trial Profile
Incidence and risk factors of infectious diseases in non-small cell lung cancer patients receiving nivolumab: A retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Jan 2019 Results investigating the incidence of infections during nivolumab treatment, and the risk factors associated with infections, published in the Respiratory Medicine.
- 16 Nov 2017 New trial record